Multiple sclerosis. Nat Rev Dis Primer, vol.4, p.43, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-00826733
Clinical Course of Multiple Sclerosis, Cold Spring Harb Perspect Med. sept, vol.8, issue.9, p.28928, 2018. ,
Age at onset determines the occurrence of the progressive phase of multiple sclerosis, Neurology. 6 mars, vol.68, issue.10, pp.779-81, 2007. ,
, , 2018.
Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data, J Neurol. juin, vol.264, issue.6, pp.1185-92, 2017. ,
, Définition et chiffres -Fondation Sclérose en plaques
Progressive Forms of Multiple Sclerosis: Distinct Entity or Age-Dependent Phenomena, Neurol Clin. févr, vol.36, issue.1, pp.163-71, 2018. ,
Immunology of Multiple Sclerosis, Semin Neurol. avr, vol.36, issue.2, pp.115-142, 2016. ,
Immunopathology of multiple sclerosis, Nat Rev Immunol. 15 sept, vol.15, issue.9, pp.545-58, 2015. ,
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis, Brain J Neurol, vol.120, pp.2059-69, 1997. ,
Critères diagnostiques de la sclérose en plaques, Prat Neurol -FMC. mars, vol.8, issue.2, pp.118-139, 2017. ,
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology. avr, vol.46, issue.4, pp.907-918, 1996. ,
Defining the clinical course of multiple sclerosis, Neurology. 15 juill, vol.83, issue.3, pp.278-86, 2014. ,
Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome, Neurology. 3 mars, vol.72, issue.9, pp.800-805, 2009. ,
, CT-16878_OCREVUS_PICins_SEP-R_avis2_CT16878_def.pdf
,
Predicting risk of secondary progression in multiple sclerosis: A nomogram, Mult Scler Houndmills Basingstoke Engl. 1 juin, 2018. ,
,
The clinical course of multiple sclerosis, Handb Clin Neurol, vol.122, pp.343-69, 2014. ,
The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability, Brain. juill, vol.133, issue.7, pp.1914-1943, 2010. ,
Factors associated with the risk of secondary progression in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. juill, vol.14, issue.6, pp.799-803, 2008. ,
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15, J Neurol Neurosurg Psychiatry, vol.86, issue.11, pp.1202-1209, 2015. ,
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives, Lancet Neurol. févr, vol.14, issue.2, pp.208-231, 2015. ,
Natural history of multiple sclerosis: a unifying concept, Brain J Neurol. mars, vol.129, pp.606-622, 2006. ,
Defining secondary progressive multiple sclerosis, Brain J Neurol, vol.139, pp.2395-405, 2016. ,
The natural history of secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry. 1 sept, vol.81, issue.9, pp.1039-1082, 2010. ,
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies, Mult Scler J -Exp Transl Clin [Internet]. 26 juin, vol.4, issue.2, 2018. ,
,
Progression in multiple sclerosis: further evidence of an age dependent process, J Neurol Sci. 15 avr, vol.255, issue.1-2, pp.35-41, 2007. ,
Age and disability accumulation in multiple sclerosis, Neurology. 27 sept, vol.77, issue.13, pp.1246-52, 2011. ,
Age at disability milestones in multiple sclerosis, Brain. 1 mars, vol.129, issue.3, pp.595-605, 2006. ,
Clinical course of multiple sclerosis: A nationwide cohort study. Mult Scler Houndmills Basingstoke Engl, vol.23, pp.1488-95, 2017. ,
Natural history of secondaryprogressive multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. avr, vol.14, issue.3, pp.314-338, 2008. ,
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS, PLoS ONE [Internet]. 5 juin, vol.10, issue.6, 2015. ,
,
The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis, Neurology. 12 juin, vol.90, issue.24, pp.2107-2125, 2018. ,
Prognostic factors associated with long-term disability and secondary progression in patients with Multiple Sclerosis, Mult Scler Relat Disord. juill, vol.8, pp.27-34, 2016. ,
A prospective study on the prognosis of multiple sclerosis, Neurol Sci. 23 déc, vol.21, issue.0, pp.831-839, 2000. ,
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis, J Neurol Sci. 15 févr, vol.206, issue.2, pp.135-142, 2003. ,
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology. nov, vol.33, issue.11, pp.1444-52, 1983. ,
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs, Mult Scler Houndmills Basingstoke Engl. mai, vol.19, issue.6, pp.765-74, 2013. ,
Epidemiology of multiple sclerosis, Rev Neurol (Paris). janv, vol.172, issue.1, pp.3-13, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01255824
Smoking and Multiple Sclerosis: An Updated Meta-Analysis, PLoS ONE [Internet]. 13 janv, vol.6, issue.1, 2011. ,
,
A systematic review of modifiable risk factors in the progression of multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. avr, vol.23, issue.4, pp.525-558, 2017. ,
Natural history of multiple sclerosis: early prognostic factors, Neurol Clin. mai, vol.29, issue.2, pp.279-92, 2011. ,
Cigarette smoking and the progression of multiple sclerosis, Brain J Neurol. juin, vol.128, pp.1461-1466, 2005. ,
Multiple sclerosis in 2018: new therapies and biomarkers, Lancet Neurol. janv, vol.18, issue.1, pp.10-12, 2019. ,
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis, JAMA Neurol. avr, vol.72, issue.4, pp.405-418, 2015. ,
Comparative efficacy of first-line natalizumab vs IFN-? or glatiramer acetate in relapsing MS, Neurol Clin Pract. avr, vol.6, issue.2, pp.102-117, 2016. ,
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study, Lancet Neurol, vol.16, issue.4, pp.271-81, 2017. ,
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, CAMMS223 Trial Investigators, vol.359, pp.1786-801, 2008. ,
Immunomodulatory therapies delay disease progression in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.22, issue.13, pp.1732-1772, 2016. ,
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA. 15 janv, vol.321, issue.2, pp.175-87, 2019. ,
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis, Mult Scler Relat Disord. mars, vol.6, pp.57-63, 2016. ,
Betainterferon exposure and onset of secondary progressive multiple sclerosis, Eur J Neurol. juin, vol.22, issue.6, pp.990-1000, 2015. ,
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial, J Neurol Neurosurg Psychiatry. 1 août, vol.81, issue.8, pp.907-919, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00557446
, EDMUS : Le projet
,
Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France, Mult Scler Houndmills Basingstoke Engl. 13 déc, 2018. ,
Evidence for a two-stage disability progression in multiple sclerosis, Brain. juill, vol.133, issue.7, pp.1900-1913, 2010. ,
Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision, Expert Rev Neurother. mars, vol.6, issue.3, pp.357-64, 2006. ,
Epidemiology of Multiple Sclerosis, Neurol Clin, vol.34, issue.4, pp.919-958, 2016. ,
Multiple sclerosis: an immune or neurodegenerative disorder?, Annu Rev Neurosci, vol.31, pp.247-69, 2008. ,
Clinical prognostic factors in multiple sclerosis: a natural history review, Nat Rev Neurol. déc, vol.5, issue.12, pp.672-82, 2009. ,
Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis, Neurology. 25 août, vol.85, issue.8, pp.722-731, 2015. ,
, , 2019.
,
Facteurs prédictifs de passage de la Sclérose en plaques récurrente-rémittente en forme secondairement progressive en Normandie RESUME ,
, Peu de données sont disponibles sur le passage à la forme progressive (SEP-SP) chez les patients atteints de sclérose en plaques récurrente-rémittente (SEP-RR). L'objectif de l'étude est d'identifier les facteurs influençant le taux et le délai de passage en forme SP à 11 ans
Les données ont été extraites à partir du registre de l'Observatoire Français de la SEP ,
, Le « groupe converteur » comportait -moins de femmes (65% vs 74,4% ; p=0,008) -un âge moyen au début de la maladie plus élevée (35,45+/-8,83ans vs 28,66+/-9,49ans ; p<0,001) -un nombre plus élevé de patients ayant fait >2 ou ?3, patients ont été inclus dans le « groupe non converteur » et 120 dans le « groupe converteur, p.5
, La durée de la phase RR était corrélée de façon proportionnelle au délai entre la première et la seconde poussée (délai P1-P2) et au délai d'instauration d'un traitement par rapport au début de la maladie
le sexe masculin, un nombre ? 2 poussées dans les deux premières années de la maladie sont prédictifs d'un passage en forme SP à 11 ans. Bénéficier d'un TPL est plutôt protecteur. La durée de la phase RR est corrélée au délai, pp.1-2 ,
Sclérose en plaques -Secondairement progressive -Épidémiologie -Facteurs prédictifs -Normandie ,
Predictive factors for relapsing-remitting multiple sclerosis in secondary progressive form in Normandy RESUME DE LA THESE EN ANGLAIS : In the era of disease modifying treatments, little is known about conversion to the progressive phase (SP-MS) in relapsing-remitting multiple sclerosis (RR-MS) patients. The objective of the study is to identify the factors influencing the rate and the delay of a conversion to SP form within 11 years. The study was retrospective and bi-centered. The data was extracted from Observatoire Français de la SEP registry ,
, the « non-converter group » and 120 in the « converter group ». The « converter group » had -fewer women, vol.35, p.45
, 49 years ; p<0.001)-a higher number of patients who had > 2 or ?3 relapses in the first two years (25.83% vs 21.30% ; p=0.039 and 17.5% vs 11.13% ; p=0.009 respectively) and a lower number of patients treated with first-line treatment (TPL) +/-associated with second-line treatment (24.17% vs 34.5%, p <0.001 and 11.66%. vs 15.42%, p = 0.029). The duration of the RR phase was correlated proportionally with the delay between the first and the second relapses (delay P1-P2) and with the delay in initiating
, Being older at the beginning of the disease, being male, and having had more than 2 relapses in the first two years of the disease are predictive of a transition to SP form at 11 years. Benefitting from a TPL is rather protective. The duration of the RR phase is correlated with the delay, pp.1-2
Multiple sclerosis -Secondary progressive -Epidemiology -Predictive factors -Normandy ,